U.S. pharma giant copyright scrapped two experimental weight loss supplements past calendar year—a after-day-to-day capsule, lotiglipron, on account of elevated liver enzymes plus a twice-everyday capsule, danuglipron, as a result of robust Unwanted effects—but CEO Albert Bourla has mentioned the company is set to “Perform and win” while in